Efficacies of gefitinib versus paclitaxel/carboplatin for patients with advanced pulmonary adenocarcinoma
To compare the clinical efficacies of gefitinib versus paclitaxel/carboplatin in patients with advanced pulmonary adenocarcinoma. A total of 51 advanced pulmonary adenocarcinoma patients were recruited from Guangdong General Hospital during October 2006 to September 2007. Eligible patients were ≥ 18...
Gespeichert in:
| Veröffentlicht in: | Zhong hua yi xue za zhi 2014-08, Vol.94 (30), p.2337-2341 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | chi |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2341 |
|---|---|
| container_issue | 30 |
| container_start_page | 2337 |
| container_title | Zhong hua yi xue za zhi |
| container_volume | 94 |
| creator | Lou, Nana Yang, Jinji Yan, Honghong Zhou, Qing Liao, Riqiang Xu, Chongrui Huang, Yisheng Yang, Xuening Yang, Yan Gan, Bin Wu, Yilong |
| description | To compare the clinical efficacies of gefitinib versus paclitaxel/carboplatin in patients with advanced pulmonary adenocarcinoma.
A total of 51 advanced pulmonary adenocarcinoma patients were recruited from Guangdong General Hospital during October 2006 to September 2007. Eligible patients were ≥ 18 years old, either non-smokers or former light smokers and receiving no prior chemotherapy or biological/immunological therapy. According to performance status, smoking status and gender, they were selected with dynamic equilibrium randomized method 1: 1 to receive first-line gefitinib (250 mg/d) in gefitinib arm or carboplatin/paclitaxel (carboplatin, area under the curve 5 mg × ml⁻¹ × min⁻¹, 21-day cycle; paclitaxel, 200 mg/m², 21-day cycle in chemotherapy arm. The primary endpoint was progression free survival (PFS). And the secondary endpoints were objective response rate (ORR) and overall survival (OS).
They were randomized into gefitinib arm (n = 25) and paclitaxel/carboplatin arm (n = 26). The median PFS was |
| doi_str_mv | 10.3760/cma.j.issn.0376-2491.2014.30.005 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1627950633</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1627950633</sourcerecordid><originalsourceid>FETCH-LOGICAL-p196t-585fe629ae26b37b19f766d1f0ae353f131e2d4b7458196660c7cf060b42b3cc3</originalsourceid><addsrcrecordid>eNo9kMtOwzAURL0A0ar0F5CX3ST1I7HrJarKQ6rEBtaR7VyDUWKHOCnw91iisBrpzMzV6CK0oaTkUpCt7XX5XvqUQkkyKFilaMkIrUpOSkLqC7T85wu0TskbUkmuGGH0Ci1YzZVSki-RPzjnrbYeEo4Ov4Lzkw_e4BOMaU540Lbzk_6Cbmv1aOLQ6exjF8dsTR7ClPCnn96wbk86WGjxMHd9DHr8zghCzC3rQ-z1Nbp0ukuwPusKvdwdnvcPxfHp_nF_eywGqsRU1LvagWBKAxOGS0OVk0K01BENvOaOcgqsrYys6l0uCEGstI4IYipmuLV8hTa_d4cxfsyQpqb3yULX6QBxTg0VTKqaCM5z9OYcnU0PbTOMvs_Dm7_38B9QfGy6</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1627950633</pqid></control><display><type>article</type><title>Efficacies of gefitinib versus paclitaxel/carboplatin for patients with advanced pulmonary adenocarcinoma</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Lou, Nana ; Yang, Jinji ; Yan, Honghong ; Zhou, Qing ; Liao, Riqiang ; Xu, Chongrui ; Huang, Yisheng ; Yang, Xuening ; Yang, Yan ; Gan, Bin ; Wu, Yilong</creator><creatorcontrib>Lou, Nana ; Yang, Jinji ; Yan, Honghong ; Zhou, Qing ; Liao, Riqiang ; Xu, Chongrui ; Huang, Yisheng ; Yang, Xuening ; Yang, Yan ; Gan, Bin ; Wu, Yilong</creatorcontrib><description>To compare the clinical efficacies of gefitinib versus paclitaxel/carboplatin in patients with advanced pulmonary adenocarcinoma.
A total of 51 advanced pulmonary adenocarcinoma patients were recruited from Guangdong General Hospital during October 2006 to September 2007. Eligible patients were ≥ 18 years old, either non-smokers or former light smokers and receiving no prior chemotherapy or biological/immunological therapy. According to performance status, smoking status and gender, they were selected with dynamic equilibrium randomized method 1: 1 to receive first-line gefitinib (250 mg/d) in gefitinib arm or carboplatin/paclitaxel (carboplatin, area under the curve 5 mg × ml⁻¹ × min⁻¹, 21-day cycle; paclitaxel, 200 mg/m², 21-day cycle in chemotherapy arm. The primary endpoint was progression free survival (PFS). And the secondary endpoints were objective response rate (ORR) and overall survival (OS).
They were randomized into gefitinib arm (n = 25) and paclitaxel/carboplatin arm (n = 26). The median PFS was</description><identifier>ISSN: 0376-2491</identifier><identifier>DOI: 10.3760/cma.j.issn.0376-2491.2014.30.005</identifier><identifier>PMID: 25399973</identifier><language>chi</language><publisher>China</publisher><subject>Adenocarcinoma ; Adenocarcinoma of Lung ; Antineoplastic Agents ; Asian Continental Ancestry Group ; Carboplatin ; Disease-Free Survival ; Gefitinib ; Hospitals, General ; Humans ; Lung Neoplasms ; Paclitaxel ; Platinum ; Quinazolines ; Smoking</subject><ispartof>Zhong hua yi xue za zhi, 2014-08, Vol.94 (30), p.2337-2341</ispartof><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25399973$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lou, Nana</creatorcontrib><creatorcontrib>Yang, Jinji</creatorcontrib><creatorcontrib>Yan, Honghong</creatorcontrib><creatorcontrib>Zhou, Qing</creatorcontrib><creatorcontrib>Liao, Riqiang</creatorcontrib><creatorcontrib>Xu, Chongrui</creatorcontrib><creatorcontrib>Huang, Yisheng</creatorcontrib><creatorcontrib>Yang, Xuening</creatorcontrib><creatorcontrib>Yang, Yan</creatorcontrib><creatorcontrib>Gan, Bin</creatorcontrib><creatorcontrib>Wu, Yilong</creatorcontrib><title>Efficacies of gefitinib versus paclitaxel/carboplatin for patients with advanced pulmonary adenocarcinoma</title><title>Zhong hua yi xue za zhi</title><addtitle>Zhonghua Yi Xue Za Zhi</addtitle><description>To compare the clinical efficacies of gefitinib versus paclitaxel/carboplatin in patients with advanced pulmonary adenocarcinoma.
A total of 51 advanced pulmonary adenocarcinoma patients were recruited from Guangdong General Hospital during October 2006 to September 2007. Eligible patients were ≥ 18 years old, either non-smokers or former light smokers and receiving no prior chemotherapy or biological/immunological therapy. According to performance status, smoking status and gender, they were selected with dynamic equilibrium randomized method 1: 1 to receive first-line gefitinib (250 mg/d) in gefitinib arm or carboplatin/paclitaxel (carboplatin, area under the curve 5 mg × ml⁻¹ × min⁻¹, 21-day cycle; paclitaxel, 200 mg/m², 21-day cycle in chemotherapy arm. The primary endpoint was progression free survival (PFS). And the secondary endpoints were objective response rate (ORR) and overall survival (OS).
They were randomized into gefitinib arm (n = 25) and paclitaxel/carboplatin arm (n = 26). The median PFS was</description><subject>Adenocarcinoma</subject><subject>Adenocarcinoma of Lung</subject><subject>Antineoplastic Agents</subject><subject>Asian Continental Ancestry Group</subject><subject>Carboplatin</subject><subject>Disease-Free Survival</subject><subject>Gefitinib</subject><subject>Hospitals, General</subject><subject>Humans</subject><subject>Lung Neoplasms</subject><subject>Paclitaxel</subject><subject>Platinum</subject><subject>Quinazolines</subject><subject>Smoking</subject><issn>0376-2491</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kMtOwzAURL0A0ar0F5CX3ST1I7HrJarKQ6rEBtaR7VyDUWKHOCnw91iisBrpzMzV6CK0oaTkUpCt7XX5XvqUQkkyKFilaMkIrUpOSkLqC7T85wu0TskbUkmuGGH0Ci1YzZVSki-RPzjnrbYeEo4Ov4Lzkw_e4BOMaU540Lbzk_6Cbmv1aOLQ6exjF8dsTR7ClPCnn96wbk86WGjxMHd9DHr8zghCzC3rQ-z1Nbp0ukuwPusKvdwdnvcPxfHp_nF_eywGqsRU1LvagWBKAxOGS0OVk0K01BENvOaOcgqsrYys6l0uCEGstI4IYipmuLV8hTa_d4cxfsyQpqb3yULX6QBxTg0VTKqaCM5z9OYcnU0PbTOMvs_Dm7_38B9QfGy6</recordid><startdate>20140813</startdate><enddate>20140813</enddate><creator>Lou, Nana</creator><creator>Yang, Jinji</creator><creator>Yan, Honghong</creator><creator>Zhou, Qing</creator><creator>Liao, Riqiang</creator><creator>Xu, Chongrui</creator><creator>Huang, Yisheng</creator><creator>Yang, Xuening</creator><creator>Yang, Yan</creator><creator>Gan, Bin</creator><creator>Wu, Yilong</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20140813</creationdate><title>Efficacies of gefitinib versus paclitaxel/carboplatin for patients with advanced pulmonary adenocarcinoma</title><author>Lou, Nana ; Yang, Jinji ; Yan, Honghong ; Zhou, Qing ; Liao, Riqiang ; Xu, Chongrui ; Huang, Yisheng ; Yang, Xuening ; Yang, Yan ; Gan, Bin ; Wu, Yilong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p196t-585fe629ae26b37b19f766d1f0ae353f131e2d4b7458196660c7cf060b42b3cc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>chi</language><creationdate>2014</creationdate><topic>Adenocarcinoma</topic><topic>Adenocarcinoma of Lung</topic><topic>Antineoplastic Agents</topic><topic>Asian Continental Ancestry Group</topic><topic>Carboplatin</topic><topic>Disease-Free Survival</topic><topic>Gefitinib</topic><topic>Hospitals, General</topic><topic>Humans</topic><topic>Lung Neoplasms</topic><topic>Paclitaxel</topic><topic>Platinum</topic><topic>Quinazolines</topic><topic>Smoking</topic><toplevel>online_resources</toplevel><creatorcontrib>Lou, Nana</creatorcontrib><creatorcontrib>Yang, Jinji</creatorcontrib><creatorcontrib>Yan, Honghong</creatorcontrib><creatorcontrib>Zhou, Qing</creatorcontrib><creatorcontrib>Liao, Riqiang</creatorcontrib><creatorcontrib>Xu, Chongrui</creatorcontrib><creatorcontrib>Huang, Yisheng</creatorcontrib><creatorcontrib>Yang, Xuening</creatorcontrib><creatorcontrib>Yang, Yan</creatorcontrib><creatorcontrib>Gan, Bin</creatorcontrib><creatorcontrib>Wu, Yilong</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Zhong hua yi xue za zhi</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lou, Nana</au><au>Yang, Jinji</au><au>Yan, Honghong</au><au>Zhou, Qing</au><au>Liao, Riqiang</au><au>Xu, Chongrui</au><au>Huang, Yisheng</au><au>Yang, Xuening</au><au>Yang, Yan</au><au>Gan, Bin</au><au>Wu, Yilong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacies of gefitinib versus paclitaxel/carboplatin for patients with advanced pulmonary adenocarcinoma</atitle><jtitle>Zhong hua yi xue za zhi</jtitle><addtitle>Zhonghua Yi Xue Za Zhi</addtitle><date>2014-08-13</date><risdate>2014</risdate><volume>94</volume><issue>30</issue><spage>2337</spage><epage>2341</epage><pages>2337-2341</pages><issn>0376-2491</issn><abstract>To compare the clinical efficacies of gefitinib versus paclitaxel/carboplatin in patients with advanced pulmonary adenocarcinoma.
A total of 51 advanced pulmonary adenocarcinoma patients were recruited from Guangdong General Hospital during October 2006 to September 2007. Eligible patients were ≥ 18 years old, either non-smokers or former light smokers and receiving no prior chemotherapy or biological/immunological therapy. According to performance status, smoking status and gender, they were selected with dynamic equilibrium randomized method 1: 1 to receive first-line gefitinib (250 mg/d) in gefitinib arm or carboplatin/paclitaxel (carboplatin, area under the curve 5 mg × ml⁻¹ × min⁻¹, 21-day cycle; paclitaxel, 200 mg/m², 21-day cycle in chemotherapy arm. The primary endpoint was progression free survival (PFS). And the secondary endpoints were objective response rate (ORR) and overall survival (OS).
They were randomized into gefitinib arm (n = 25) and paclitaxel/carboplatin arm (n = 26). The median PFS was</abstract><cop>China</cop><pmid>25399973</pmid><doi>10.3760/cma.j.issn.0376-2491.2014.30.005</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0376-2491 |
| ispartof | Zhong hua yi xue za zhi, 2014-08, Vol.94 (30), p.2337-2341 |
| issn | 0376-2491 |
| language | chi |
| recordid | cdi_proquest_miscellaneous_1627950633 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Adenocarcinoma Adenocarcinoma of Lung Antineoplastic Agents Asian Continental Ancestry Group Carboplatin Disease-Free Survival Gefitinib Hospitals, General Humans Lung Neoplasms Paclitaxel Platinum Quinazolines Smoking |
| title | Efficacies of gefitinib versus paclitaxel/carboplatin for patients with advanced pulmonary adenocarcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T06%3A23%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacies%20of%20gefitinib%20versus%20paclitaxel/carboplatin%20for%20patients%20with%20advanced%20pulmonary%20adenocarcinoma&rft.jtitle=Zhong%20hua%20yi%20xue%20za%20zhi&rft.au=Lou,%20Nana&rft.date=2014-08-13&rft.volume=94&rft.issue=30&rft.spage=2337&rft.epage=2341&rft.pages=2337-2341&rft.issn=0376-2491&rft_id=info:doi/10.3760/cma.j.issn.0376-2491.2014.30.005&rft_dat=%3Cproquest_pubme%3E1627950633%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1627950633&rft_id=info:pmid/25399973&rfr_iscdi=true |